Low-dose oral methotrexate in chronic progressive multiple sclerosis: Analyses of serial MRIs

Neurology

Volumn 47, Issue 5, 1996, Pages 1153-1157

  Goodkin, D E ^a   Rudick, R A ^b   Vanderbrug Medendorp, S ^c   Daughtry, M M ^b   Van Dyke, C ^c  

^a UCSF Multiple Sclerosis Center   (United States)

^b Mellen Center for Multiple Sclerosis Treatment and Research   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029854588     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.5.1153     Document Type: Article

References (14)

1. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate is effective in reducing the rate of progression of neurological impairment in patients with chronic progressive multiple sclerosis. Ann Neurol 1995; 37:30-40.
2. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate (MTX) for chronic progressive multiple sclerosis: Design of a randomized placebocontrolled trial with sample size benefits from composite outcome variable. Preliminary data on toxicity. Online J Curr Clin Trials [serial online] 1992 Sep 25;1992(Doc No 19).
3. Fischer JS, Goodkin DE, Rudick RA, et al. Low-dose (7.5 mg) oral methotrexate improves neuropsychological function in patients with chronic progressive multiple sclerosis [abstract]. Ann Neurol 1994;36:289.
4. Poser CM, Paty DW, Schneiber L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
5. Goodkin DE, Ross JS, VanderBrug Medendorp S, Konecsni J, Rudick RA. MRI lesion enlargement in multiple sclerosis: disease-related activity, chance occurrence, or measurement artifact? Arch Neurol 1992;49:261-264.
6. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:12-22.
7. Scheffe H. The analysis of variance. New York: John Wiley and Sons, 1959:56-59.
8. Dupont WD, Plummer WD. Power and sample size calculations: a review and computer program. Control Clin Trials 1990;11:116-128.
9. Paty DW, Li DKB, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
10. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44:635-641.
11. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45:1808-1814.
12. Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI. Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994;57:1070-1072.
13. Filippi M, Campi A, Martinelli V, et al. A brain MRI study of different types of chronic-progressive multiple sclerosis. Acta Neurol Scand 1995;91:231-233.
14. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.